Two pathways to recurring BV identified in couples study — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Monash University and Melbourne Sexual Health Centre researchers identified two distinct pathways to recurring bacterial vaginosis: infection persistence despite a weeklong antibiotic course, and re-infection from male partners.
- Published in The Lancet Obstetrics, Gynaecology & Women's Health, the study tracked 188 couples in which women received a weeklong oral antibiotic course and men received both oral and topical antimicrobials.
- Lead author Dr. Lenka Vodstrcil said roughly one-third of women whose BV returned had microbiomes suggesting they had not cleared their BV before resuming sex after treatment, making them nearly three times more likely to get BV again within four weeks.
- The new findings build on a March 2024 study from the same group that found concurrent treatment of women and their male partners with antibiotics cut BV recurrence by more than 60%.
- The research flagged a previously underexplored factor: 30% of female participants used an intrauterine device (IUD), which the study said "could enhance the persistence of bacterial vaginosis following treatment in some women," though further research is needed.
- Vodstrcil's team plans to trial longer antibiotic courses and combinations of multiple antibiotics to break the cycle of two, three, or four repeat antibiotic rounds many BV patients endure each year.
- Senior author Prof. Catriona Bradshaw said the participant pool was "representative of urban Australia" and that results "might not be generalisable to other global populations, including those in low-income and middle-income countries and in other settings with a high burden of bacterial vaginosis."
Why it matters: This is the largest heterosexual-couples study of concurrent BV treatment to date, and it splits recurrence into two clinically addressable causes — persistent infection that survives antibiotics and re-infection from partners. That dual-pathway framing lets clinicians tailor regimens: longer or combination antibiotics for women whose infections persist, plus partner retreatment for reinfection, potentially ending the repeat-course cycle that affects about one in five women receiving concurrent treatment.
Ask SkimNews
